Right-sided heart failure and tricuspid regurgitation (TR) are associated with poor quality of life and an increased risk of hospitalization and mortality. The aim of this study was to assess the safety and efficacy of tricuspid transcatheter edge-to-edge repair (T-TEER) combined with optimal medical treatment (OMT), compared to OMT alone, over a one-year follow-up.
The study enrolled symptomatic patients (functional class II-IV) with TR higher than severe who were not surgical candidates. The primary endpoint was a clinical composite that included the occurrence of a cardiovascular event (hospitalization or death), changes in functional class (FC), and patient-reported symptoms (patient global assessment, PGA).
Secondary endpoints included changes in regurgitation, quality of life according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), major adverse events (MAE), and safety events.
At one year of follow-up, 74.1% of the T-TEER group showed improvement in the primary endpoint, compared to 40.6% in the OMT group (Better Rank 0.67; 95% confidence interval [CI] 0.61-0.72; p<0.001).
In conclusion, the authors highlighted that T-TEER therapy significantly and safely improved clinical events in patients with severe symptomatic TR.
Presented by Erwan Donal at the Hot-Line Sessions, ESC Congress 2024, August 30-September 2, London, England.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
 están asociadas con una baja calidad de vida y un mayor riesgo de hospitalizaciones y mortalidad.){kind=link}